Deformation-based morphometry applied to FDG PET data reveals hippocampal atrophy in Alzheimer's disease.
Humans
Alzheimer Disease
/ diagnostic imaging
Hippocampus
/ diagnostic imaging
Male
Aged
Female
Fluorodeoxyglucose F18
Atrophy
/ pathology
Positron-Emission Tomography
/ methods
Magnetic Resonance Imaging
/ methods
Retrospective Studies
Positron Emission Tomography Computed Tomography
/ methods
Aged, 80 and over
Middle Aged
ROC Curve
Alzheimer’s disease
Atrophy
FDG PET
MRI
Morphometry
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
06
02
2024
accepted:
16
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
epublish
Résumé
Cerebral atrophy is a key finding in patients with dementia and usually determined on MRI. We tested whether cerebral atrophy can be imaged with FDG PET by applying deformation-based morphometry (DBM). We retrospectively identified 26 patients with a biomarker-supported clinical diagnosis of Alzheimer's disease (AD) who had received FDG PET on a fully-digital PET/CT system and structural MRI and compared them to 13 healthy elderly controls (HEC). We performed DBM with FDG PET data (FDG-DBM). As a reference standard for determining atrophy we used voxel-based morphometry of MRI data (MRI-VBM). For conventional analysis of hypometabolism, scaled FDG PET scans (reference: brain parenchyma) were compared between groups. Receiver operating characteristic (ROC) analyses were performed. ROI read-outs were tested for associations with cognitive test performance. FDG-DBM showed abnormalities in AD mainly in the bilateral hippocampi. Similarly, MRI-VBM showed hippocampal atrophy. By contrast, conventional FDG PET analysis revealed reduced bilateral temporo-parietal FDG uptake (all p < 0.05, FWE-corrected). FDG-DBM measures of the hippocampus significantly separated AD from HEC with an AUC of 0.81; MRI-VBM achieved an AUC of 0.87; the difference between the two ROC curves was not significant (p = 0.40). Whereas FDG uptake of the hippocampus did not separate AD from HEC, FDG uptake of the Landau Meta-ROI achieved an AUC of 0.88. Verbal memory was significantly associated with FDG-DBM measures of the hippocampus (p = 0.009), but not of the Landau Meta-ROI (p > 0.1). The opposite held true for conventional FDG uptake (p > 0.1 and p = 0.001, respectively). Hippocampal atrophy in AD can be detected by applying DBM to clinical, fully-digital FDG PET. It correlates with cognitive performance and might constitute a biomarker of neurodegeneration that is complementary to conventional FDG PET analysis of regional hypometabolism.
Identifiants
pubmed: 39198541
doi: 10.1038/s41598-024-70380-z
pii: 10.1038/s41598-024-70380-z
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20030Informations de copyright
© 2024. The Author(s).
Références
Karas, G. B. et al. A comprehensive study of gray matter loss in patients with Alzheimer’s disease using optimized voxel-based morphometry. Neuroimage 18, 895–907 (2003).
doi: 10.1016/S1053-8119(03)00041-7
pubmed: 12725765
Pieperhoff, P. et al. Deformation field morphometry reveals age-related structural differences between the brains of adults up to 51 years. J Neurosci 28, 828–842 (2008).
doi: 10.1523/JNEUROSCI.3732-07.2008
pubmed: 18216191
pmcid: 6671008
Ozden, C. et al. FDG uptake in the basal forebrain as measured by digital high-resolution PET is a promising marker of basal forebrain degeneration in the lewy body disease spectrum: A pilot study. Clin Nucl Med 45, 261–266 (2020).
doi: 10.1097/RLU.0000000000002960
pubmed: 32108697
Yang, J. et al. Voxelwise meta-analysis of gray matter anomalies in Alzheimer’s disease and mild cognitive impairment using anatomic likelihood estimation. J Neurol Sci 316, 21–29 (2012).
doi: 10.1016/j.jns.2012.02.010
pubmed: 22385679
Schroeter, M. L. & Neumann, J. Combined imaging markers dissociate Alzheimer’s disease and frontotemporal lobar degeneration: An ALE meta-analysis. Front Aging Neurosci 3, 10 (2011).
doi: 10.3389/fnagi.2011.00010
pubmed: 21811457
pmcid: 3141339
Darby, R. R., Joutsa, J. & Fox, M. D. Network localization of heterogeneous neuroimaging findings. Brain 142, 70–79 (2019).
doi: 10.1093/brain/awy292
pubmed: 30551186
Matsunari, I. et al. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer’s disease: Aging effect on diagnostic performance. J Nucl Med 48, 1961–1970 (2007).
doi: 10.2967/jnumed.107.042820
pubmed: 18006622
Maldjian, J. A. & Whitlow, C. T. Whither the hippocampus? FDG-PET hippocampal hypometabolism in Alzheimer disease revisited. AJNR Am J Neuroradiol 33, 1975–1982 (2012).
doi: 10.3174/ajnr.A3113
pubmed: 22700745
pmcid: 7964612
Berres, M., Monsch, A. U., Bernasconi, F., Thalmann, B. & Stahelin, H. B. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Inform 77, 195–199 (2000).
pubmed: 11187541
Morris, J. C. et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 39, 1159–1165 (1989).
doi: 10.1212/WNL.39.9.1159
pubmed: 2771064
Speck, I. et al. (18)F-FDG PET imaging of the inferior colliculus in asymmetric hearing loss. J Nucl Med 61, 418–422 (2020).
doi: 10.2967/jnumed.119.231407
pubmed: 31481576
Eickhoff, S. B. et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 25, 1325–1335 (2005).
doi: 10.1016/j.neuroimage.2004.12.034
pubmed: 15850749
Scahill, R. I. et al. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60, 989–994 (2003).
doi: 10.1001/archneur.60.7.989
pubmed: 12873856
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32:1207–1218
Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 14:535–562